Our Focus

In order to develop new ways to treat infections caused by superbugs (multidrug resistant bacteria), which are germs that don't respond to many standard antibiotics, this study was conducted in partnership with prominent microbiologists both regionally and internationally. Dealing with bacteria that create metallo-β-lactamases (MBLs), which are enzymes that degrade antibiotics and render them useless, which is one of the most difficult problems.

What is it about?

We evaluated a combination of two antibiotics:

• Aztreonam: effective against MBL-producing bacteria but not others.
• Ceftazidime-avibactam: effective against most bacteria, but not those producing MBLs.

Why it matters

Superbugs are an increasing global concern. Finding innovative strategies to treat infections is critical for keeping them from spreading and causing harm. Our findings offer hope for more effective medicines, particularly for infections that are difficult to cure with present antibiotics.

Citation

Madhu Rai, Shaoli Basu, Priti Kambli, Lizanne Drego, Priyanka Patel, Anjali Shetty, Camilla Rodrigues. Unleashing the potent synergy of ceftazidime-avibactam and aztreonam against metallo-beta-lactamase producing Enterobacterales in the battle against antibiotic resistance. An in vitro study, Indian Journal of Medical Microbiology, Volume 54, 2025, 100819, ISSN 0255-0857, https://doi.org/10.1016/j.ijmmb.2025.100819